BioCentury

8:00 AM GMT, Dec 19, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Regulatory

Brilinta regulatory update

Germany's Federal Joint Committee (G-BA) issued a final benefit assessment for cardiovascular drug Brilique ticagrelor from AstraZeneca. G-BA said Brilique provides

Read the full 216 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.